Air Purification in Healthcare. Elevated.
Across the globe, subclinical infections and hospital-acquired infections (HAIs), or nosocomial infections, represent a real health and financial crisis. In the United States alone, the Centers for Disease Control and Prevention (CDC) estimates that more than 1.7 million patients have developed HAIs, leading to more than 99,000 deaths annually. The cost to our nation? As much as $45 billion every year.
Clearly, despite the use of rigorous infection control, subclinical infections and HAIs remain a persistent problem. Traditional protocols focus on the patient, provider and surface areas. Current literature indicates that airborne transmission and surface contamination are virtually impossible to separate.
But with the LifeAire Systems technology, significantly reducing subclinical infections and HAIs is possible. This revolutionary technology engages multi-staged levels of air filtration, purification and inactivation media to aggressively remove chemical, particulate and infectious biological pathogens from both outside and re-circulated air.
“Hospital acquired infections represent a health and financial crisis for hospitals and patients around the world.”
Kathryn C. Worrilow, Ph.D., LifeAire Systems, LLC
The LifeAire System is mathematically and genomically modeled to kill or inactivate the most infectious biological pathogens-including but not limited to anthrax spores, tuberculosis, COVID-19 (Coronavirus), and influenza-on a single pass through the system.
Designed to kill the most difficult biological threats
The LifeAire System was initially designed to protect the environment of the human embryo in the In Vitro Fertilization (IVF) laboratory. To achieve this, it was critical that the system remediate all chemical and biological contaminants from the air. Therefore, LifeAire was genomically and mathematically modeled to kill the anthrax spore, the most difficult biological spore to kill.
Because of its effectiveness towards the anthrax spore, the LifeAire System is able to provide a 9-log* reduction of all infectious airborne bacterial, viral and fungal pathogens. Airborne bacterial, fungal and viral pathogens represent a consistent threat to both the IVF and healthcare environment.
LifeAire will deliver a kill/disinfection rate of 145-log** against the airborne COVID-19 virus. As reference, sterility is defined by a 6-log*** reduction. The susceptibility to germicidal kill of any microorganism is determined by its genomic sequence of ACTG, and in particular, the recurrence of TT and TTT. The viral kill delivered by the LifeAire System provides a 145-log kill specific to the genomic sequence of the COVID-19 virus.
The kill mechanisms used in our system have been tested by the National Homeland Security Research Center. Our technology has received (26) U.S. and international patents to date.
* 9-log kill equals 1 X 109 remediation efficiency
** 145-log kill equals 1 X 10145 remediation efficiency
*** 6-log kill equals 1 X 106 remediation efficiency
Why not HEPA filtration?
The kill ability provided by our technology was intentional as the capture ability employed by HEPA filtration, the most common means of air filtration used in healthcare, cannot provide comprehensive remediation when pathogen sizes fall within the range of 0.1 to 0.3 microns.